The efficacy and safety of third line H. pylori eradication therapy with sitafloxacin, metronidazole and PPI
Phase 3
- Conditions
- H. pylori-positve patients after the 2nd line eradication failure or penicillin-allergic patients
- Registration Number
- JPRN-UMIN000013195
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with allergy for quinolones 2. Patients with allergy for PPIs 3. Patients with severe liver injury and/or severe renal damage 4. Pregnancy or possible pregnancy 5. Patients who were recognized as inappropriate for entry
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The efficacy of H. pylori eradication
- Secondary Outcome Measures
Name Time Method adverse events MIC of STFX,MNZ, gyaA mutation
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sitafloxacin and metronidazole synergy in H. pylori eradication?
How does sitafloxacin/metronidazole/PPI triple therapy compare to bismuth-based regimens in third-line H. pylori treatment?
Which biomarkers predict response to sitafloxacin-based therapy in penicillin-allergic H. pylori patients?
What adverse events are associated with sitafloxacin/metronidazole/PPI triple therapy and their management strategies?
Are there alternative fluoroquinolone combinations for third-line H. pylori eradication compared to sitafloxacin regimens?